What Whan In Pharm. Co., Ltd. does

Whan In Pharm. Co., Ltd. (환인제약) is a South Korea-based CNS (central nervous system) specialty pharmaceutical company founded in 1982 and listed on the Korea Exchange (KOSDAQ). The company develops, manufactures, and distributes prescription and OTC pharmaceutical products targeting psychiatric and neurological disorders, including anti-epileptics, ADHD treatments, dementia therapies, antipsychotics, antidepressants, and autoimmune-disease treatments such as JAK inhibitors. It maintains an inventory of 200-plus products in its catalog at per-tablet pricing between KRW 751 and KRW 8,307, distributed domestically through a regulated wholesale channel. Manufacturing is anchored at the Hyangnam factory acquired from Janssen in 2020, which is equipped with blister packaging lines configured for export-oriented production and operates under EAEU GMP and Japan PMDA approvals.

The company operates a hybrid business model. In Korea, it sells through pharmaceutical wholesalers under reimbursement pricing with upper price limits. Internationally, it pursues an enterprise B2B export and licensing model, shipping generic and First-Generic formulations to partners including TEVA, Unilab (Philippines), EAEU regional distributors, and ANXO (Taiwan) for OROS osmotic-controlled-release ADHD medication. Wholly-owned subsidiary AsYou (애즈유) extends into consumer health with NMN-based anti-aging supplements, joint-care products, and cosmeceutical skincare distributed via direct e-commerce (including Coupang) and co-marketing partnerships such as the October 2025 collaboration with LOUD Corporation.

Whan In Pharm differentiates through a 40-plus-year CNS domain track record, a stack of regulatory credentials (ISO 9001, ISO 37001, ISO/IEC 27001; EAEU GMP; Japan PMDA), and exclusive or first-mover formulations including the 2026 launch of the first tablet form of atomoxetine in Korea across six pediatric-friendly dosage strengths. A 2025-filed NMN formulation patent underpins the AsYou brand. Export revenue is explicitly guided to scale from 20B KRW (2023) to 100B KRW (2028), implying roughly 5x growth anchored by the TEVA export partnership.

Name

Whan In Pharm. Co., Ltd.

Legal name

Whan In Pharm. Co., Ltd.

Website

https://whanin.co.kr

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

11–50 employees

Short description

Whan In Pharm. Co., Ltd. is a South Korean CNS specialty pharmaceutical company founded in 1982 and listed on KOSDAQ, developing and exporting generic and First-Generic drugs for epilepsy, ADHD, dementia, and autoimmune diseases, with a consumer health subsidiary AsYou.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• CNS specialty pharmaceuticals
• Generic drug development
• Pharmaceutical contract manufacturing
• Healthcare supplements
• Pharmaceutical export distribution

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription and OTC pharmaceutical products in Korea, including CNS drugs, anti-epileptics, dementia treatments, ADHD treatments, autoimmune disease treatments
2. International Export Sales: Export of pharmaceutical products to international markets including Philippines, Mongolia, Yemen, EAEU region, Japan, Mexico. Includes CDMO manufacturing services for overseas partners.
3. Healthcare Supplements (AsYou Brand): Sale of health supplements and wellness products through subsidiary AsYou, including NMN products, joint health supplements, skincare products

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Whan In Pharm manufactures and sells a portfolio of CNS-focused prescription generic pharmaceuticals (anti-epileptics, ADHD treatments, dementia/Alzheimer's therapies, antipsychotics, antidepressants) plus cardiovascular, autoimmune (JAK inhibitors), and OTC cognitive products. The company also operates a wholly owned subsidiary AsYou that markets consumer health supplements (NMN-based anti-aging, joint care), cosmeceuticals (mineral sunscreen), and eye-care products, and provides GMP-certified CDMO services to international partners.

Product overview

Whan In Pharm. Co., Ltd. is a CNS-focused Korean pharmaceutical company offering a diversified portfolio of prescription drugs and health supplements. The pharmaceutical portfolio centers on CNS (central nervous system) treatments including anti-epileptics (브리바®정, 네오팻정), ADHD treatments (환인아토목세틴정/캡슐), dementia/Alzheimer's treatments (환인메만틴정, 도멘시아정), and psychiatric medications (항우울제, 조현병치료제, 항불안제), complemented by cardiovascular products (듀카포지정, 트윈포지정, 콤비로칸정), autoimmune treatments (토파시즈®정), antibiotics, and general pharmaceuticals (환인징코정). The company's subsidiary AsYou (애즈유) operates in healthcare and cosmeceutical segments with products like NMN-based anti-aging supplements (생생바인 NMN NAD+ 리포좀 글루타치온), joint health supplements (생생바인 콘드로이친Q), and sunscreen products (더마린 라인). Products are distributed through prescription (전문의약품) and general (일반의약품) channels, with recent expansion into export markets and CDMO partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• AsYou (애즈유): Healthcare and wellness brand offering health supplements including NMN products, collagen, and glutathione supplements
• DermaLin (더마린)
• Eye Ref (아이리프)

Products and services

• Briva Tablets (브리바정, brivaracetam) Third-generation anti-epileptic drug (brivaracetam) available in 5 strengths (10, 25, 50, 75, 100mg) for the treatment of partial-onset seizures in patients 16 years and older. Whan In Pharm is the only company in Korea with the 75mg dosage for liver-impairment patients.
• Topacise Tablets (토파시즈정, tofacitinib) JAK inhibitor (tofacitinib) for autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, available in 5mg and 10mg oral formulations. Targets inflammatory cytokines with oral administration unlike biologics.
• Whanin Atomoxetine Tablets (환인아토목세틴정) ADHD treatment (atomoxetine) available in 6 strengths (10, 18, 25, 40, 60, 80mg) as the first tablet formulation approved in Korea. Non-psychoactive selective norepinephrine reuptake inhibitor approved for children 6 years and older and adults.
• Dukappojei Tablets (듀카포정, fimasartan/amlodipine) Antihypertensive combination drug (fimasartan/amlodipine) for essential hypertension when single therapy fails to control blood pressure. Available in 30/2.5mg, 60/2.5mg, and 60/5mg strengths with once-daily dosing.
• Whanin Memantine Tablets (환인메만틴정) Alzheimer's disease treatment (memantine) available in 5mg, 10mg, and 20mg dosages. NMDA receptor antagonist that inhibits abnormal NMDA receptor activation to improve memory and slow disease progression.
• Whanin Ginkgo 240mg Tablets (환인징코정) Non-prescription cognitive improvement product containing 240mg ginkgo biloba extract for concentration, memory decline, and dizziness symptoms associated with cerebrovascular conditions. Once-daily dosing with or without food.
• Niseon Tablets (니세온정) Prescription brain function improvement drug in Whan In Pharm's CNS portfolio. Listed as a 전문의약품 (prescription drug) brain function improver on the company website.
• Dommensia Tablets (도멘시아정, donepezil) Prescription dementia treatment (donepezil) in Whan In Pharm's CNS portfolio. Listed as a 전문의약품 (prescription drug) dementia therapeutic on the company website.
• AsYou Saengsaeng Vine NMN NAD+ Liposome Glutathione (쌍쌍바인 NMN NAD+ 리포좀 글루타치온) Anti-aging health supplement from the AsYou brand combining NMN, fisetin, liposome glutathione, low-molecular collagen, and quercetin. Targets cellular health, energy metabolism, skin improvement, brain health, and muscle recovery for health-conscious consumers.
• AsYou Saengsaeng Vine ChondroitinQ Joint Health (쌍쌍바인 초록입홍합 콘드로이친Q) Joint health supplement from the AsYou brand combining green-lipped mussel powder and chondroitin. Targeted at a broad demographic from seniors to active younger generations for joint and cartilage support.
• DermaLin Mild Moisturizer Mineral Suncream (더마린 마일드 모이스처 미네랄 선크림) Triple-functionality cosmeceutical sunscreen from the DermaLin sub-brand of AsYou with SPF50+ PA++++ rating, providing UV protection, wrinkle improvement, and whitening. Zinc oxide 100% mineral formula with blue light protection, niacinamide, adenosine, and patented Handelin extract.
• AsYou Eye Ref (아시유 아이리프) Eye health specialist brand under the AsYou subsidiary targeting vision care and eye health. Marketed with celebrity couple Kim So-hyun and Son Jun-ho as exclusive models representing trust and health image.
• Pharmaceutical CDMO Services Contract Development & Manufacturing Organization (CDMO) services offered to international pharmaceutical partners, particularly in the EAEU region. Backed by EAEU GMP recertification, GMP-certified facilities (Hyangnam factory), and blister packaging equipment. Supports First Generic product launches in Eurasian Economic Union markets.

Quantifiable outcome

• Export revenue growth from 20B KRW (2023) to projected 100B KRW (2028) - approximately 5x increase
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, strategic and minor.

• TEVAcoreChannel Partner/ Reseller/ Distributor · 17 June 2026Strategic export partnership with global leading generic pharmaceutical company TEVA. Exports are rapidly increasing following partnership establishment, with 2028 export projection of 100 billion KRW.
• ANXO (Taiwan)coreStrategic or Co-development Partner · 29 October 2025Exclusive development and supply contract for OROS ADHD generic medication applying same technology as Concerta OROS. ANXO provides formulation technology while Whan In Pharm handles domestic supply and market authorization.
• LOUD CorporationstrategicGTM or Marketing Partner · 21 October 2025Strategic partnership between AsYou healthcare brand and K-culture leading entertainment company. Collaboration for wellness lifestyle content, global market expansion, and marketing synergy combining pharmaceutical credibility with K-culture appeal.
• PharmaTria IrelandminorGTM or Marketing Partner · 21 October 2025Subsidiary partnership under LOUD Corporation alliance. PharmaTria Ireland CEO Kim Jun-soo attended the signing ceremony representing K-pop musical actors Kim So-hyun and Son Jun-ho as brand ambassadors for AsYou's EyeRef brand.
• JanssenstrategicOthers · 1 January 2020Acquired Hyangnam factory from Janssen in 2020 for manufacturing capacity expansion and export-oriented production including blister packaging facilities.
• Unilab (Philippines)coreChannel Partner/ Reseller/ DistributorExport partnership with Philippines' largest and leading pharmaceutical company in Southeast Asia for CNS products. 10+ years of strategic partnership established.
• EAEU Regional PartnerscoreChannel Partner/ Reseller/ DistributorStrategic partnerships with regional pharmaceutical companies across EAEU (Eurasian Economic Union) markets. CDMO business yielding tangible results following successful GMP recertification.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Viatris: Global generics and specialty pharma formed from Mylan/Pfizer Upjohn combination, with extensive CNS portfolio. Comparable as a global generic pharma incumbent competing in the same export markets Whan In Pharm targets.
• Dong-A ST: Korean pharmaceutical company with established CNS products (e.g., Stillen, Motilitone) alongside biologics and OTC. Comparable Korean pharma peer with CNS presence and similar export ambitions, though larger in scale.
• Daewoong Pharmaceutical: Korea's third-largest pharmaceutical company, operating across CNS, gastrointestinal, dermatology, and biosimilars. Comparable as a Korean pharma peer with overlapping CNS exposure but significantly larger scale and broader portfolio.
• Chong Kun Dang (CKD) Pharmaceutical: Mid-to-large Korean pharmaceutical company with generics, biosimilars, and specialty drugs including CNS portfolio. Comparable as a Korean pharma peer with overlapping CNS generic exposure.
• Celltrion: Korea's largest biopharma by market cap, focused on biosimilars with growing small-molecule and CDMO operations. Relevant as a Korean listed pharma with international growth ambitions, but limited CNS overlap.
• Hanmi Pharmaceutical: Larger Korean pharmaceutical incumbent with established CNS franchises alongside oncology, diabetes, and consumer health. Comparable as a Korean pharma with CNS depth, but materially larger and more diversified than Whan In Pharm.
• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with a major CNS portfolio. Listed as both a strategic export partner and a broad incumbent comparable — relevant for benchmarking scale, regulatory reach, and global generic distribution dynamics.
• Yuhan Corporation: Korea's largest pharmaceutical company by domestic revenue, operating across prescription drugs, consumer health, and APIs. Comparable as a Korean pharma incumbent, though broader therapeutic and geographic scope.

Direct peers

• SK Biopharmaceuticals: Korea-listed CNS specialty pharmaceutical company focused on epilepsy (Cenobamate/XCopri), ADHD, and orphan CNS indications. Most directly comparable peer — similar CNS specialty positioning, KOSDAQ listing, and recent transition from licensing-led to commercial-scale growth.
• Daehan New Pharm: Korean mid-cap pharmaceutical company with CNS-focused portfolio including Alzheimer's, anti-epileptics, and psychiatric medications. Closest peer by therapeutic focus, scale, and Korean generics-to-specialty positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/whanin-pharm-co-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Whan In Pharm. Co., Ltd.